Search

Displaying results 3791 - 3800 of 9702 in total
  1. Drug

    D2C7 immunotoxin

    go.drugbank.com/drugs/DB17540
    Investigational

    D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL.

  2. Drug

    PLX51107

    go.drugbank.com/drugs/DB17543
    Investigational

    PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family.

  3. Drug

    Timdarpacept

    go.drugbank.com/drugs/DB17544
    Investigational

    IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. … [A257261] IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).

  4. Drug

    Jaktinib

    go.drugbank.com/drugs/DB17545
    Investigational

    Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.

  5. Drug

    APR-548

    go.drugbank.com/drugs/DB17546
    Investigational

    APR-548 is an analog of [eprenetapopt] and a reactivator of mutant p53.

  6. Drug

    Anzurstobart

    go.drugbank.com/drugs/DB17547
    Investigational

    Anzurstobart is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα) on monocytes and macrophages to potently block the CD47-SIRPα interaction.

  7. Drug

    PF-04856884

    go.drugbank.com/drugs/DB17550
    Investigational

    PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor.

  8. Drug

    Pucotenlimab

    go.drugbank.com/drugs/DB17552
    ApprovedInvestigational

    Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours.

  9. Drug

    PF-08046040

    go.drugbank.com/drugs/DB17555
    Investigational

    SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).

  10. Drug

    Rineterkib

    go.drugbank.com/drugs/DB17560
    Investigational

    Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel